HaiderSMahdiMDMPH

Obstetrics & Gynecology • Detroit, MI

Gynecologic Oncology

Staff, Cleveland Clinic

Join to view full profile

Dr. Mahdi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mahdi's full profile

Already have an account?

Office
3990 John R 7 Brush North
Wayne State University Detroit Medical Centerobgyn
Detroit, MI 48201
Phone+1 734-444-6406

Fax+1 216-444-9423

Education & Training

Cleveland Clinic FoundationFellowship, Gynecologic Oncology, 2012 - 2015
University of WashingtonResidency, Obstetrics and Gynecology, 2009 - 2012
Wayne State University School of MedicineInternship, Transitional Year, 2008 - 2009
University of Al-Mustansiriyah College of MedicineClass of 2004

Certifications & Licensure

MI State Medical License 2023 - 2026
OH State Medical License 2012 - 2026
PA State Medical License 2020 - 2024
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Publications & Presentations

PubMed

Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892).
Sarah E Taylor, Sarah Behr, Kristine L Cooper, Haider Mahdi, Denise Fabian
Cancer Chemotherapy and Pharmacology. 2024-12-14
A Core NRF2 Gene Set Defined Through Comprehensive Transcriptomic Analysis Predicts Selective Drug Resistance and Poor Multicancer Prognosis.
George Luo, Harshita Kumar, Kristin Aldridge, Stevie Rieger, EunHyang Han
Antioxidants & Redox Signaling. 2024-12-01
Association of neighborhood social vulnerability with ovarian cancer survival.
Lauren Borho, Esther Elishaev, Riyue Bao, Emily O'Brien, Kaitlyn Dinkins
Gynecologic Oncology. 2024-11-21

Lectures

The role of proinflammatory immune (IFN-gamma) gene signature in predicting prognosis and response to chemotherapy in uterine carcinoma.
2019 ASCO Annual Meeting - 6/1/2019
The role of different TGFÎ² signatures in predicting outcome in high grade serous ovarian carcinoma.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

ALX Oncology Doses First Patient in Trial of Evorpacept for Ovarian CancerMay 10th, 2023
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian CancerMay 9th, 2023
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb's Immune Checkpoint Inhibitor OPDIVOFebruary 22nd, 2022
Join now to see all